An immune system defect makes affected individuals vulnerable to severe viral diseases such as influenza or COVID-19. It is ...

Interestingly, the researchers also found that by blocking these THBS1 with antibodies the damage could be reversed. These ...

A Stanford-led team has found two antibodies that can work together to defeat all SARS-CoV-2 variants. More research is needed, but the approach could help in the development of treatments to keep ...

No mechanism-associated safety issues have been identified for VISTA-blocking antibodies. In addition to its in-house VISTA program, Kineta is focusing discovery stage research efforts on ...

Sun Pharma to acquire Checkpoint Therapeutics for $4.10 per share, with potential CVR. FDA approves Unloxcyt, the first PD-L1 blocker for advanced cSCC.